Vitreous and aqueous penetration of orally administered moxifloxacin in humans

Eye

Volumn 20, Issue 11, 2006, Pages 1273-1278

  Vedantham, V ^a   Lalitha, P ^a   Velpandian, T ^b   Ghose, S ^b   Mahalakshmi, R ^a   Ramasamy, K ^a  

^a ARAVIND EYE HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; ECTOPIA LENTIS; ENDOPHTHALMITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA HOLE; STAPHYLOCOCCUS EPIDERMIDIS; UNSPECIFIED SIDE EFFECT; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 33750685948     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702094     Document Type: Article

References (20)

1. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996; 122: 1-17.
2. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995; 113: 1479-1496.
3. el-Massry A, Meredith TA, Aguilar HE, Shaarawy A, Kincaid M, Dick J et al. Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration. Am J Ophthalmol 1996; 122: 684-689.
4. Aguilar HE, Meredith TA, Shaarawy A, Kincaid M, Dick J. Vitreous cavity penetration of ceftazidime after intravenous administration. Retina 1995; 15: 154-159.
5. Cekic O, Batman C, Yasar U, Basci NE, Bozkurt A, Kayaalp SO et al. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration. Eye 1999; 13: 555-558.
6. Donnenfeld D, Perry HD, Snyder RW, Moadel R, Elsky M, Jones H et al. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol 1997; 115: 173-176.
7. Fiscella RG, Nguyen TKP, Cwik MJ, Phillpotts BA, Friedlander SM, Alter DC et al. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999; 106: 2286-2290.
8. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, Carrasco-Font C. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. J Cataract Refract Surg 2001; 27: 1969-1974.
9. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol 2003; 121: 345-350.
10. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005; 123: 39-44.
11. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-651.
12. Mather R, Karanchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002; 133: 463-466.
13. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365-387.
14. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC et al. Gatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003; 136: 500-505.
15. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones. J Antimicrob Chemother 1999; 43(suppl B): 1-11.
16. Keating GM, Scott LJ. Moxifloxacin: A review of its use in the management of bacterial infections. Drugs 2004; 64: 2347-2377.
17. Talwar D, Kulkarni A, Azad R, Gupta SK, Velpandian T, Sharma Y et al. Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. Invest Ophthalmol Vis Sci 2003; 44: 505-509.
18. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 1999; 106: 1313-1318.
19. Hariprasad SM, Mieler WE, Shah GK, Blinder KJ, Apte RS, Holekamp NM et al. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans Am Ophthalmol Soc 2004; 102: 149-155 discussion 155-157.
20. Liu W, Liu QF, Perkins R, Drusano G, Louie A, Madu A et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: Physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob Agents Chemother 1998; 42: 1417-1423.